Comparison of pain and efficacy of darbepoetin alfa and epoetin beta pegol treatment in patients receiving peritoneal dialysis

Journal of Nippon Medical School

Volumn 82, Issue 1, 2015, Pages 21-26

  Otsuka, Tomoyuki ^a   Sakai, Yukinao ^a   Yui, Shizuka ^a   Sukegawa, Masami ^a   Suzuki, Anna ^a   Mugishima, Koji ^a   Sumi, Yuichiro ^a   Otsuka, Yusuke ^a   Tsuruoka, Shuichi ^b  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Change ratio; Darbepoetin alfa; Epoetin beta pegol; Pain comparison; Peritoneal dialysis

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; BIOLOGICAL MARKER; ERYTHROPOIETIN; MACROGOL DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FACES PAIN SCALE; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE PAIN; IRON BINDING CAPACITY; IRON METABOLISM; MALE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PAIN MEASUREMENT; PERITONEAL DIALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; ADVERSE EFFECTS; BLOOD; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; METABOLISM; MIDDLE AGED; PAIN; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

AGED; ANEMIA; BIOMARKERS; DARBEPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; JAPAN; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PERITONEAL DIALYSIS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925070807     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.82.21     Document Type: Article

References (26)

1. Horl WH: Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013; 9: 291-301.
2. Schmid H, Schiffl H, Lederer SR: Erythropoiesisstimulating agents, hypertension and left ventricular hy pertrophy in the chronic kidney disease patient. Curr Opin Nephrol Hypertens 2011; 20: 465-470.
3. Del Vecchio L, Cavalli A, Tucci B, Locatelli F: Chronic kidney disease-associated anemia: new remedies. Curr Opin Investig Drugs 2010; 11: 1030-1038.
4. Bamgbola OF: Pattern of resistance to erythropoietinstimulating agents in chronic kidney disease. Kidney Int 2011; 80: 464-474.
5. Perez-Ruixo JJ, Cucala-Ramos M, Garcia-Gonzalo E, Del Val Romero B, Valveny N: Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis. Br J Clin Pharmacol 2013; 75: 15-25.
6. Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF: Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2014; 3: Cd 009297.
7. Theodoridis M, Passadakis P, Kriki P, et al.: Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients. Perit Dial Int 2005; 25: 564-569.
8. Suzuki H, Inoue T, Watanabe Y, et al.: Testing a single monthly dose of darbepoetin alpha to maintain hemoglobin levels in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2011; 27: 60-64.
9. Ter Wee PM, de Koter Y, van der Veer O, van Vliet MH: Immediate pain sensation is less with subcutaneous epoietin-beta compared to subcutaneous darbepoietinalpha. Clin Nephrol 2009; 72: 177-180.
10. Pannier A, Jordan P, Dougherty FC, Bour F, Reigner B: Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa. Curr Med Res Opin 2007; 23: 3025-3032.
11. Canaud B, Mingardi G, Braun J, et al.: Intravenous C.E.R. A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23: 3654-3661.
12. Forni V, Bianchi G, Ogna A, et al.: Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial. BMC Nephrol 2013; 14: 157-166.
13. Dellanna F, Winkler RE, Bozkurt F, et al.: Dosing strategies for conversion of haemodialysis patients from shortacting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. Int J Clin Pract 2011; 65: 64-72.
14. Carrera F, Lok CE, de Francisco A, et al.: Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010; 25: 4009-4017.
15. Mann JF, de Francisco A, Nassar G, Canaud B: Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol 2011; 76: 9-15.
16. Tomlinson D, von Baeyer CL, Stinson JN, Sung L: A systematic review of faces scales for the self-report of pain intensity in children. Pediatrics 2010; 126: e1168-1198.
17. Williamson A, Hoggart B: Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005; 14: 798-804.
18. Klinger M, Arias M, Vargemezis V, et al.: Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50: 989-1000.
19. Kawakami K, Takama H, Nakashima D, Tanaka H, Uchida E, Akizawa T: Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. Eur J Clin Pharmacol 2008; 65: 169-178.
20. Levin NW, Fishbane S, Canedo FV, et al.: Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370: 1415-1421.
21. Macdougall IC, Robson R, Opatrna S, et al.: Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E. R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211-1215.
22. Koch M, Treiber W, Fliser D: Effective achievement of hemoglobin stability with once-monthly C.E.R.A. in peritoneal dialysis patients: a prospective study. Clin Drug Investig 2013; 33: 699-706.
23. Hiramatsu M, Momoki R, Kashio Y, et al.: Effect of C.E.R. A. on maintaining hemoglobin levels in the peritoneal dialysis patients with renal anemia. Jin to Touseki 2013; 74: 1164-1168 (in Japanese).
24. Yamashita M: Changing Back Effect of Darbepoetin Alfa on Anemia Treatment in Hemodialysis Patients Treating with Epoetin Beta Pegol. Ther Res 2012; 33: 1095-1100 (in Japanese).
25. Hiramatsu M, Hotta O, Masakane I, et al.: Effect of Haemoglobin (Hb) Maintenance of Subcutaneous (SC) or lntravenous (IV) C. E. R. A. (Continuous Erythropoietin Receptor Activator) in Renal Anemia Patients on Peritoneal Dialysis. Jpn Pharmacol Ther 2011; 39 (supplement): s69-s78 (in Japanese).
26. Oka M, Mochizuki T, Kamiyama M, et al.: Evaluation of Subcutaneous Injection Pain with C.E.R.A. and Darbepoetin Alfa in CAPD Patients. Ther Res 2012; 33: 413-419 (in Japanese).